OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Nvidia Options Price in $280 Billion Earnings Swing 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Trump Buys SpaceX Shares After Record IPO 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Add as a preferred source on Google
EAST RUTHERFORD, N.J., April 26, 2018 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that first quarter 2018 financial results will be released on Thursday, May 3, 2018 before the market opens.
The Company will host a conference call to discuss the financial results.
| First Quarter 2018 Earnings Conference Call | |
| When: | Thursday, May 3, 2018 at 8:30 a.m. Eastern Time |
| Dial-in: | 1-877-260-1479 for U.S. |
| 1-334-323-0522 for International | |
| Passcode: 5093025 | |
| Dial-in Replay: | 1-888-203-1112 for U.S. |
| 1-719-457-0820 for International | |
| Passcode: 5093025 | |
| Available through Thursday, May 10, 2018 | |
| Webcast: | www.cambrex.com |
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and continuous processing. For more information, please visit www.cambrex.com.
| Contact: | Stephanie LaFiura |
| Investor Relations Associate | |
| Tel: 201-804-3037 | |
| Email: [email protected] |
